I. Micallef

发表

Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.

A. Nademanee, J. Dipersio, G. Bridger, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.

A. Nademanee, J. Dipersio, J. Kaufman, 2009, Blood.

Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines.

T. Habermann, P. L. Bergsagel, R. Fonseca, 2010, Mayo Clinic proceedings.

Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma

S. Ansell, A. Dispenzieri, A. Tefferi, 2006, Bone Marrow Transplantation.

Early lymphocyte recovery post‐autologous haematopoietic stem cell transplantation is associated with better survival in Hodgkin's disease

S. Ansell, S. Markovic, S. Geyer, 2002, British journal of haematology.

Posttransplantation thrombotic thrombocytopenic purpura: a single-center experience and a contemporary review.

A. Dispenzieri, A. Tefferi, S. Ansell, 2003, Mayo Clinic proceedings.

Vitamin D insufficiency is associated with an increased risk of early clinical failure in follicular lymphoma

J. Cerhan, T. Habermann, S. Slager, 2017, Blood Cancer Journal.

The effect of absolute lymphocyte count recovery kinetics on survival after autologous stem cell transplantation for non-Hodgkin's lymphoma

S. Ansell, A. Dispenzieri, A. Tefferi, 2005, Leukemia & lymphoma.

Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report.

A. Nademanee, J. Dipersio, J. Kaufman, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The mTORC1 Inhibitor Everolimus Combined with R-CHOP-21 for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Safety and Efficacy Results of a Phase I and Feasibility Trial NCCTG 1085 (Alliance)

T. Habermann, S. Ansell, T. Witzig, 2016 .

Phase I study of a modified regimen of ⁹⁰Yttrium-ibritumomab tiuxetan for relapsed or refractory follicular or transformed CD20+ non-Hodgkin lymphoma.

S. Shen, R. Meredith, S. Knox, 2013, Cancer biotherapy & radiopharmaceuticals.

Day 15 peripheral blood lymphocyte/monocyte ratio post-autologous peripheral hematopoietic stem cell transplantation and survival in diffuse large B-cell lymphoma.

S. Ansell, S. Markovic, W. Hogan, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study

T. Habermann, S. Ansell, C. Reeder, 2011, Leukemia.

Outcomes of Autologous Stem Cell Transplant Consolidation in Primary CNS Lymphoma: A Mayo Clinic Experience.

T. Habermann, S. Ansell, B. Laplant, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B‐cell non‐Hodgkin lymphoma

Brian J. Smith, Y. Asmann, T. Habermann, 2013, American journal of hematology.

Detection of extranodal and spleen involvement by FDG‐PET imaging predicts adverse survival in untreated follicular lymphoma

T. Habermann, S. Ansell, T. Witzig, 2019, American journal of hematology.

Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma.

T. Lister, R. Gupta, A. Rohatiner, 2000, The hematology journal : the official journal of the European Haematology Association.

A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B‐cell lymphoma

T. Habermann, S. Ansell, S. Ansell, 2006, Cancer.

Food‐frequency questionnaire‐based estimates of total antioxidant capacity and risk of non‐Hodgkin lymphoma

J. Cerhan, T. Habermann, S. Slager, 2012, International journal of cancer.

Superior Survival in Primary Systemic Amyloidosis Patients Undergoing Peripheral Blood Stem Cell Transplant : A Case Control Study Running Head: Survival in AL, Case Control Study

R. Fonseca, S. Ansell, A. Dispenzieri, 2004 .

Genetic susceptibility to Hodgkin's disease and secondary neoplasias: FISH analysis reveals patients at high risk of developing secondary neoplasia.

T. Lister, A. Rohatiner, M. Neat, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Detection of chromosome abnormalities pre-high-dose treatment in patients developing therapy-related myelodysplasia and secondary acute myelogenous leukemia after treatment for non-Hodgkin's lymphoma.

T. Lister, A. Rohatiner, M. Neat, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and efficacy of upfront plerixafor + G‐CSF versus placebo + G‐CSF for mobilization of CD34+ hematopoietic progenitor cells in patients ≥60 and <60 years of age with non‐Hodgkin's lymphoma or multiple myeloma

A. Nademanee, J. Dipersio, P. Stiff, 2013, American journal of hematology.

Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.

A. Nademanee, J. Dipersio, G. Bridger, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide

A. Ho, P. Mcsweeney, P. Gandhi, 2011, Bone Marrow Transplantation.

Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide

A. Ho, P. Mcsweeney, G. Calandra, 2011, Bone Marrow Transplantation.

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Comparative Trial of AMD3100 (Plerixafor)+G-CSF vs. G-CSF+Placebo for Mobilization in Multiple Myeloma (MM) Patients for Autologous Hematopoietic Stem Cell (aHSC) Transplantation.

A. Nademanee, J. Dipersio, G. Bridger, 2007 .

Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study.

S. Ansell, S. Markovic, D. Gastineau, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase II trial of the oral mTOR inhibitor everolimus (RAD001) for patients with relapsed or refractory lymphoma

T. Habermann, S. Ansell, S. Markovic, 2007 .

Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas.

T. Habermann, S. Ansell, Hui Tang, 2011, Blood.

Outcomes in primary cutaneous diffuse large B‐cell lymphoma, leg type

T. Habermann, S. Ansell, T. Witzig, 2021, Hematological Oncology.

Absolute Lymphocyte Count Recovery Predicts Superior Survival and Is Independent of the International Prognostic Index in Patients Treated with CHOP or R-CHOP Chemotherapy for Diffuse Large B Cell Lymphoma.

T. Habermann, S. Ansell, S. Markovic, 2005 .

Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study.

J. Cerhan, A. Feldman, T. Habermann, 2017, International journal of epidemiology.

A Phase II study of 153Sm‐EDTMP and high‐dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma

D. Dingli, S. Ansell, A. Dispenzieri, 2010, American journal of hematology.

Hematopoietic stem cells from poor and good mobilizers are qualitatively equivalent

Liuyan Jiang, V. Roy, D. Gastineau, 2012, Transfusion.

The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation

T. Habermann, T. Witzig, B. Laplant, 2010, Cancer.

Effectiveness of second line salvage chemotherapy with ifosfamide, carboplatin, and etoposide in patients with relapsed diffuse large B-cell lymphoma not responding to cis-platinum, cytosine arabinoside, and dexamethasone

T. Habermann, S. Ansell, S. Markovic, 2007, Leukemia & lymphoma.

Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression

A. Feldman, S. Ansell, T. Witzig, 2022, Journal for ImmunoTherapy of Cancer.

Long-Term Health-Related Quality of Life of Autologous Hematopoietic Cell Transplantation Patients and Nontransplant Patients With Aggressive Lymphoma: A Prospective Cohort Analysis

J. Cerhan, S. Ansell, S. Ehlers, 2022, JCO oncology practice.

Ongoing trials with yttrium 90-labeled ibritumomab tiuxetan in patients with non-Hodgkin's lymphoma.

I. Micallef, 2004, Clinical lymphoma.

Risk of histological transformation and therapy‐related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma

T. Habermann, S. Ansell, S. Markovic, 2017, British journal of haematology.

A Phase II Study of Nivolumab in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

A. Feldman, S. Ansell, T. Witzig, 2019, Blood.

Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti‐CD20): a retrospective cohort analysis

T. Lister, A. Norton, J. Foran, 2001, British journal of haematology.

Resolution of CD8+ Lymphomatoid Papulosis After Surgical Excision of the Type AB-Thymoma

M. Camilleri, F. Medeiros, R. El-Azhary, 2009, The American Journal of dermatopathology.

PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts

Jason R. Young, J. Cerhan, A. Feldman, 2021, Blood Cancer Journal.

Positron emission tomography using F-18 fluorodeoxyglucose pre- and post-autologous stem cell transplant in non-Hodgkin's lymphoma

G. Wiseman, I. Micallef, P. Johnston, 2008, Bone Marrow Transplantation.

The International Prognostic Index predicts outcome after histological transformation of low-grade non-Hodgkin lymphoma

T. Habermann, S. Ansell, S. Markovic, 2006, Leukemia & lymphoma.

Impact of lymphoma survivorship clinic visit on patient-centered outcomes.

T. Habermann, S. Ansell, S. Markovic, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia

S. Ansell, A. Dispenzieri, A. Tefferi, 2006, Bone Marrow Transplantation.

Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma

M. Gertz, D. Gastineau, I. Micallef, 2010, Bone Marrow Transplantation.

Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol.

J. Dipersio, G. Bridger, G. Calandra, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Interleukin-15 Affects Patient Survival through Natural Killer Cell Recovery after Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin Lymphomas

S. Ansell, S. Markovic, W. Hogan, 2010, Clinical & developmental immunology.

Impact of autograft-absolute lymphocyte count on survival in double/triple hit lymphomas post-autologous stem cell transplantation

S. Ansell, S. Markovic, D. Inwards, 2022, Leukemia & lymphoma.

Therapeutic options in patients with lymphoma and severe liver dysfunction.

T. Habermann, R. Fonseca, S. Ansell, 2004, Mayo Clinic proceedings.

Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-Hodgkin lymphoma and low circulating peripheral blood CD34+ cells.

A. Nademanee, J. Dipersio, G. Calandra, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma.

J. Cerhan, T. Habermann, S. Slager, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bowel perforation in intestinal lymphoma: incidence and clinical features.

T. Habermann, J. Donohue, S. Ansell, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma.

A. Nademanee, J. Dipersio, G. Bridger, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient.

M. Territo, P. McCarthy, K. Badel, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

High-Dose Methotrexate in Patients With Lymphoma: Predictors of a Complicated Course

T. Habermann, S. Ansell, T. Witzig, 2022, JCO oncology practice.

Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma

A. Dispenzieri, A. Tefferi, S. Ansell, 2003, Bone Marrow Transplantation.

Absolute lymphocyte count predicts therapeutic efficacy and survival at the time of radioimmunotherapy in patients with relapsed follicular lymphomas

T. Habermann, S. Ansell, S. Markovic, 2007, Leukemia.

Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report

D. Dingli, A. Dispenzieri, Shaji K. Kumar, 2010, Leukemia & lymphoma.

PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts

Jason R. Young, J. Cerhan, A. Feldman, 2021, Blood Cancer Journal.

Low risk of symptomatic venous thromboembolic events during growth factor administration for PBSC mobilization

D. Dingli, S. Ansell, A. Dispenzieri, 2011, Bone Marrow Transplantation.

Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative.

D. Dingli, A. Dispenzieri, Shaji K. Kumar, 2008, Mayo Clinic proceedings.

G-CSF plus plerixafor (Mozobil) to mobilize hematopoietic stem cells in patients with thrombocytopenia or leukopenia prior to auto-SCT

E. Jacobsen, G. Calandra, P. Gandhi, 2013, Bone Marrow Transplantation.

Long-term outcome of allogeneic stem cell transplantation in chronic lymphocytic leukemia: analysis after a minimum follow-up of 5 years

A. Dispenzieri, A. Tefferi, S. Ansell, 2008, Leukemia & lymphoma.

Central nervous system involvement by mantle cell lymphoma

T. Habermann, S. Ansell, T. Witzig, 2021, Leukemia & lymphoma.

Stem cell transplantation for the management of primary systemic amyloidosis.

A. Dispenzieri, A. Tefferi, S. Ansell, 2002, The American journal of medicine.

Role of systemic high‐dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990‐2018

T. Habermann, J. Pulido, T. Witzig, 2018, American journal of hematology.

Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome

D. Dingli, A. Bryce, A. Dispenzieri, 2008, European journal of haematology.

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.

Deborah A. Bowen, A. Feldman, T. Habermann, 2017, Blood.

High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance)

T. Habermann, S. Ansell, B. Laplant, 2017, Blood Cancer Journal.

Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.

T. Habermann, S. Ansell, T. Witzig, 2016, The Lancet. Haematology.

Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma

T. Habermann, S. Ansell, D. Northfelt, 2017, American journal of hematology.

Peripheral T-cell lymphoma following rituximab therapy for B-cell lymphoma.

T. Lister, A. Rohatiner, J. Foran, 1999, Blood.

A phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma.

T. Lister, R. Gupta, J. Radford, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Outcomes in primary cutaneous diffuse large B‐cell lymphoma, leg type

T. Habermann, S. Ansell, T. Witzig, 2021, Hematological oncology.

Outcomes of older adults with non-Hodgkin lymphoma undergoing autologous stem cell transplantation: a Mayo Clinic Cohort Analysis.

S. Ansell, W. Hogan, D. Inwards, 2022, Transplantation and cellular therapy.

The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma

T. Habermann, S. Ansell, S. Markovic, 2011, Leukemia.

Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma.

T. Lister, J. Radford, A. Rohatiner, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas

T. Habermann, S. Ansell, S. Markovic, 2007, British journal of haematology.

T. Lister, A. Rohatiner, M. Neat, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predicting survival for diffuse large B‐cell lymphoma patients using baseline neutrophil/lymphocyte ratio

T. Habermann, S. Markovic, K. Ristow, 2010, American journal of hematology.

CD34+ cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies

S. Ansell, M. Lacy, W. Hogan, 2010, Bone Marrow Transplantation.

A Risk Adapted Approach Utilizing Plerixafor in Autologous Peripheral Blood Stem Cell Mobilization.

D. Dingli, A. Dispenzieri, Shaji K. Kumar, 2009 .

Characteristics of late transplant‐associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation

D. Dingli, A. Dispenzieri, Shaji K. Kumar, 2020, American journal of hematology.

Autograft immune content and survival in non-Hodgkin's lymphoma: A post hoc analysis.

S. Ansell, S. Markovic, D. Inwards, 2019, Leukemia research.

Immunologic Autograft Engineering and Survival in Non-Hodgkin Lymphoma.

S. Ansell, V. Suman, S. Markovic, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Predicting Peripheral Blood Stem Cell Harvest Failure Using Circulating CD34 Levels: Developing Target-Based Cut-Points for Early Intervention

D. Dingli, A. Dispenzieri, S Kumar, 2010, Bone Marrow Transplantation.

Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization.

D. Dingli, A. Dispenzieri, Shaji K. Kumar, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A Framework for Outpatient Infusion of Antispike Monoclonal Antibodies to High-Risk Patients with Mild-to-Moderate Coronavirus Disease-19

Karen J. Reinschmidt, S. Tulledge-Scheitel, L. Lutwick, 2021, Mayo Clinic Proceedings.

Clinical Study Day 100 Peripheral Blood Absolute Lymphocyte / Monocyte Ratio and Survival in Classical Hodgkin ’ s Lymphoma Postautologous Peripheral Blood Hematopoietic Stem Cell Transplantation

S. Ansell, S. Markovic, W. Hogan, 2015 .

Day 100 Peripheral Blood Absolute Lymphocyte/Monocyte Ratio and Survival in Classical Hodgkin's Lymphoma Postautologous Peripheral Blood Hematopoietic Stem Cell Transplantation

S. Ansell, S. Markovic, W. Hogan, 2013, Bone marrow research.

Incidence of supraventricular arrhythmias during autologous peripheral blood stem cell transplantation.

D. Dingli, S. Ansell, A. Dispenzieri, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Infused autograft lymphocyte to monocyte ratio predicts survival in classical Hodgkin lymphoma

S. Ansell, S. Markovic, W. Hogan, 2015, Journal of blood medicine.

Infused Autograft Lymphocyte to Monocyte Ratio and Survival in Classical Hodgkin Lymphoma

S. Ansell, S. Markovic, W. Hogan, 2014 .

Infused autograft lymphocyte to monocyte ratio and survival in diffuse large B cell lymphoma.

S. Ansell, S. Markovic, W. Hogan, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Clinical Impact and Resource Utilization After Stem Cell Mobilization Failure in Patients with Multiple Myeloma and Lymphoma.

M. Gertz, D. Gastineau, I. Micallef, 2009 .

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

T. Habermann, M. Gupta, S. Ansell, 2010, Leukemia.

Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma.

J. Cerhan, P. Kurtin, T. Habermann, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study.

T. Therneau, R. Fonseca, S. Ansell, 2004, Blood.

Randomized Phase II Study of Interleukin-12 in Combination with Rituximab in Previously Treated Non-Hodgkin's Lymphoma Patients

S. Ansell, C. Erlichman, S. Geyer, 2006, Clinical Cancer Research.

Clinical heterogeneity of diffuse large B cell lymphoma following failure of front‐line immunochemotherapy

J. Cerhan, T. Habermann, S. Ansell, 2017, British journal of haematology.

A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma

T. Habermann, S. Ansell, C. Reeder, 2010, American journal of hematology.

Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institution.

T. Habermann, S. Ansell, S. Markovic, 2016, Blood.

Leukemic High Grade B Cell Lymphoma is Associated With MYC Translocation, Double Hit/Triple Hit Status, Transformation, and CNS Disease Risk: The Mayo Clinic Experience.

T. Habermann, H. Tun, Liuyan Jiang, 2022, Clinical lymphoma, myeloma & leukemia.

Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.

J. Cerhan, G. Salles, T. Habermann, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical manifestations of, diagnostic approach to, and treatment of neurolymphomatosis in the rituximab era.

T. Habermann, D. Lachance, R. Spinner, 2021, Blood advances.

Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP.

T. Witzig, A. Dogan, M. Maurer, 2012, Blood.

Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma

T. Habermann, S. Ansell, S. Markovic, 2010, Leukemia.

Time of relapse after initial therapy significantly adds to the prognostic value of the IPI-R in patients with relapsed DLBCL undergoing autologous stem cell transplantation

S. Ansell, S. Ansell, D. Inwards, 2008, Bone Marrow Transplantation.

Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma.

B. B. Weitner, A. Rademaker, L. Gordon, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: A phase II trial in the North Central Cancer Treatment Group

D. Moore, C. Reeder, S. Geyer, 2008, Leukemia & lymphoma.

Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy.

J. Cerhan, T. Habermann, S. Ansell, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of lenalidomide combined with R-CHOP (R2CHOP) on negative prognostic impact of nongerminal center (non-GCB) phenotype in newly diagnosed diffuse large B-cell lymphoma: A phase 2 study.

T. Habermann, S. Ansell, C. Reeder, 2014 .

The absolute monocyte count is associated with overall survival in patients newly diagnosed with follicular lymphoma

T. Habermann, S. Ansell, S. Markovic, 2012, Leukemia & lymphoma.

Persistent mediastinal FDG uptake on PET-CT after frontline therapy for Hodgkin lymphoma: biopsy, treat or observe?

Jason R. Young, T. Habermann, S. Ansell, 2020, Leukemia & lymphoma.

Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study

T. Habermann, S. Ansell, T. Witzig, 2021, Blood cancer journal.

Final results of NCCTG N0489: Epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma.

D. Moore, T. Witzig, M. Maurer, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed Aggressive Non-Hodgkin Lymphoma (NHL).

T. Habermann, H. Tun, C. Reeder, 2007 .

AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantation in non-Hodgkin lymphoma.

S. Markovic, D. Gastineau, D. Inwards, 2007, Clinical lymphoma & myeloma.

Dendritic Cell Vaccine Treatment for B-Cell Non-Hodgkin Lymphoma: Clinical Trial in Progress

A. Dietz, T. Atwell, S. Ansell, 2014 .

Patients Enrolled in the Gimema Lal 0496 Protocol Presentation and Correlation with Response to Induction Treatment in Adult T-cell Acute Lymphoblastic Leukemia: Biologic Profile At

T. Habermann, M. Vignetti, A. Guarini, 2005 .

Plerixafor and G-CSF for autologous stem cell mobilization in patients with NHL, Hodgkin’s lymphoma and multiple myeloma: results from the expanded access program

P. Mcsweeney, S. Devine, D. Johns, 2013, Bone Marrow Transplantation.

Infusion of autograft natural killer cell/CD14+HLA-DRDIM cell ratio predicts survival in lymphoma post autologous stem cell transplantation

S. Ansell, S. Markovic, W. Hogan, 2018, Bone Marrow Transplantation.

AMD3100 Combined with Standard Doses of G-Csf Leads to Rapid, Consistent Mobilization of Hematopoietic Progenitor Cells in Patients with Non-Hodgkin’s Lymphoma (NHL) and Multiple Myeloma.

G. Tricot, M. Territo, P. McCarthy, 2004 .

Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016

T. Habermann, P. L. Bergsagel, R. Fonseca, 2017, JAMA oncology.

Majority of patients receiving initial therapy with lenalidomide-based regimens can be successfully mobilized with appropriate mobilization strategies

D. Dingli, A. Dispenzieri, M. Gertz, 2012, Leukemia.

Hematopoietic recovery kinetics predicts for poor CD34+ cell mobilization after cyclophosphamide chemotherapy in multiple myeloma

D. Dingli, A. Dispenzieri, Shaji K. Kumar, 2012, American journal of hematology.

Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation.

T. Therneau, M. Burritt, A. Jaffe, 2004, Blood.

Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials.

J. Cerhan, T. Molina, G. Salles, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Personalized risk prediction for event‐free survival at 24 months in patients with diffuse large B‐cell lymphoma

J. Cerhan, R. Gascoyne, C. Copie-Bergman, 2016, American journal of hematology.

Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma

T. Habermann, S. Ansell, S. Markovic, 2014, Leukemia & lymphoma.

Peripheral blood absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles predicts clinical outcomes in classical Hodgkin lymphoma

T. Habermann, S. Ansell, S. Markovic, 2012, Blood Cancer Journal.

Reply to ‘Claimed association of absolute lymphocyte count with therapeutic efficacy of radio-immunotherapy in patients with indolent lymphoma cannot be verified in an independence data set’ by Mark J Bishton et al

T. Habermann, S. Ansell, S. Markovic, 2008, Leukemia.

Absolute lymphocyte count predicts overall survival in follicular lymphomas

T. Habermann, S. Ansell, S. Markovic, 2006, British journal of haematology.

The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma.

T. Habermann, S. Ansell, H. Tun, 2015, Blood.

Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma

S. Ansell, D. Inwards, L. Costa, 2008, British journal of haematology.

New-onset lymphopenia assessed during routine follow-up is a risk factor for relapse postautologous peripheral blood hematopoietic stem cell transplantation in patients with diffuse large B-cell lymphoma.

S. Ansell, S. Markovic, W. Hogan, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A phase 1 trial of 90Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma

D. Dingli, A. Dispenzieri, S. Ansell, 2017, Bone Marrow Transplantation.

Motixafortide (BL-8040) and G-CSF Versus Placebo and G-CSF to Mobilize Hematopoietic Stem Cells for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: The Genesis Trial

J. Dipersio, M. Qazilbash, Á. Illés, 2021, Blood.

Autograft-Absolute Lymphocyte Count Infusion Predicts Survival in Double/Triple Hit Lymphomas Post-Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation

S. Ansell, S. Markovic, D. Inwards, 2021, Blood.

Immunologic Autograft Engineering: 13 Years Follow-up

S. Ansell, S. Markovic, D. Inwards, 2021, Blood.

Infused autograft-absolute lymphocyte count predicts superior survival in Diffuse Large B-Cell Lymphoma patients post-autologous peripheral blood hematopoietic stem cell transplantation: a matched-control study.

S. Ansell, S. Markovic, J. Winters, 2021, Transplantation and cellular therapy.

Day 100 Absolute Monocyte/Lymphocyte Prognostic Score and Survival Post Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation in Diffuse Large B-Cell Lymphoma

S. Ansell, S. Markovic, W. Hogan, 2013 .

Oral Tipifarnib (R115777) Has Single Agent Anti-Tumor Activity in Patients with Relapsed Aggressive Non-Hodgkin Lymphoma (NHL): Results of a Phase II Trial in the University of Iowa/Mayo Clinic Lymphoma SPORE (CA97274).

T. Habermann, S. Ansell, S. Kaufmann, 2006 .

Plerixafor (Mozobil ®)Plus G-CSF Is Effective in Mobilizing Hematopoietic Stem Cells in Patients with Concurrent Thrombocytopenia Undergoing Autologous Hematopoietic Stem Cell Transplantation.

E. Jacobsen, P. Mody, S. Marulkar, 2009 .

Predicting Poor Peripheral Blood Stem Cell Mobilization in Multiple Myeloma (MM) Using Initial Peripheral CD34 Counts: Developing Target-Based Cut-Points for Early Intervention.

D. Dingli, A. Dispenzieri, Shaji K. Kumar, 2009 .

Plerixafor Can Predictably Mobilize Hematopoietic Stem Cells in Patients With Multiple Myeloma Previously Treated With Lenalidomide

P. Mcsweeney, D. Huebner, I. Micallef, 2009 .

Prior Rituximab Exposure Does Not Appear to Affect Time to Treatment Failure After Radioimmunotherapy

T. Habermann, S. Ansell, T. Witzig, 2011 .

Absolute monocyte/lymphocyte count prognostic score is independent of immunohistochemically determined cell of origin in predicting survival in diffuse large B-cell lymphoma

T. Habermann, S. Ansell, S. Markovic, 2012, Leukemia & lymphoma.

Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular lymphocyte‐predominant Hodgkin lymphoma

T. Habermann, S. Ansell, S. Markovic, 2012, British journal of haematology.

Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin’s lymphoma

T. Habermann, S. Ansell, S. Markovic, 2012, Haematologica.

Positive positron emission tomography (PET) pre-autologous stem cell transplant (ASCT) in non-Hodgkin lymphoma (NHL) does not preclude successful outcome

V. Lowe, S. Ansell, D. Inwards, 2006 .

Plerixafor (Mozobi ® )Plus G-CSF Is More Effective Than Placebo Plus G-CSF in Mobilizing CD34+ Hematopoietic Stem Cells in Patients with Multiple Myeloma Who Have Low (<20 cells/μl) Peripheral Blood CD34+ Cell Count.

A. Nademanee, J. Dipersio, P. Stiff, 2009 .

Transplantation for Immunoglobulin Light Chain Amyloidosis. A Statistical Analysis of Factors Predicitng Outcome In Over 400 Patients

D. Dingli, A. Dispenzieri, Shaji K. Kumar, 2010 .

The mTORC 1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma

T. Habermann, S. Ansell, H. Tun, 2015 .

Impact of Cell of Origin on Outcomes After Autologous Hematopoietic Cell Transplant in Diffuse Large B-Cell Lymphoma.

S. Ansell, H. Tun, C. Reeder, 2021, Clinical lymphoma, myeloma & leukemia.

Combination of lenalidomide with R-CHOP (R2CHOP) as an initial therapy for aggressive B-cell lymphomas: A phase I/II study.

T. Habermann, S. Ansell, C. Reeder, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Germinal center B (GCB) and non‐GCB cell‐like diffuse large B cell lymphomas have similar outcomes following autologous haematopoietic stem cell transplantation

A. Feldman, S. Ansell, D. Inwards, 2008, British journal of haematology.

History of autoimmune conditions and lymphoma prognosis

J. Cerhan, C. Flowers, A. Feldman, 2018, Blood Cancer Journal.

Hypomagnesemia at the time of autologous stem cell transplantation for patients with diffuse large B-cell lymphoma is associated with an increased risk of failure

M. Mcmahon, S. Ansell, M. Hathcock, 2021, Blood cancer journal.

A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B‐cell non‐Hodgkin lymphoma: ECOG3402

R. Advani, R. Gascoyne, S. Horning, 2015, British journal of haematology.

Fimepinostat (CUDC‐907) in patients with relapsed/refractory diffuse large B cell and high‐grade B‐cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses

Mariano J. Alvarez, Sonali M. Smith, A. Califano, 2021, British journal of haematology.

Combination of Lenalidomide with R-CHOP (R2CHOP) Is Well-Tolerated and Effective As Initial Therapy for Aggressive B-Cell Lymphomas - A Phase II Study

T. Habermann, S. Ansell, C. Reeder, 2012 .

A Phase III, Multicenter, Randomized, Double-Blind, Placebo Controlled, Comparative Trial of AMD3100 (Plerixafor)+G-CSF vs. Placebo+G-CSF in Non-Hodgkin’s Lymphoma (NHL) Patients for Autologous Hematopoietic Stem Cell (aHSC) Transplantation.

J. Dipersio, G. Bridger, G. Calandra, 2007 .

Successful Stem Cell Mobilization Rescue by AMD3100 (Plerixafor)+G-CSF for Patients Who Failed Primary Mobilization: Results from the Phase III (3101-NHL) Study.

J. Dipersio, G. Bridger, G. Calandra, 2007 .

A Risk Adapted Approach Utilizing Plerixafor In Autologous Peripheral Blood Stem Cell Mobilization

D. Dingli, A. Dispenzieri, S. Ansell, 2010 .

Timing of autologous stem cell transplantation from last chemotherapy affects lymphocyte collection and survival in non-Hodgkin lymphoma

S. Ansell, S. Markovic, D. Gastineau, 2006, British journal of haematology.

Effect of AMD3100 on T Lymphocyte Subpopulations in Apheresis Products of Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation for Non Hodgkin Lymphoma.

A. Dispenzieri, Shaji K. Kumar, M. Gertz, 2005 .

PD-1 Blockade with Pembrolizumab in Relapsed CLL Including Richter's Transformation: An Updated Report from a Phase 2 Trial (MC1485)

Deborah A. Bowen, A. Feldman, T. Habermann, 2016 .

90Y Ibritumomab Tiuxetan (Zevalin®; 90YZ) Doses Calculated To Deliver up to 1500 cGy to Critical Organs May Be Safely Combined with High-Dose BEAM and Autotransplant in NHL.

A. Rademaker, L. Gordon, J. Winter, 2006 .

Initial results of a pilot study of epratuzumab and rituximab in combination with CHOP chemotherapy (ER-CHOP) in previously untreated patients with diffuse large B-cell lymphoma (DLBCL).

T. Habermann, S. Horning, S. Ansell, 2004, Journal of Clinical Oncology.

T. Habermann, S. Ansell, T. Witzig, 2021, Blood Cancer Journal.

A phase II study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma

D. Moore, T. Witzig, M. Maurer, 2008 .

Diagnosis-to-Treatment Interval (DTI) Remains Associated with Adverse Clinical Characteristics and Outcome in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma Treated on Clinical Trials

J. Cerhan, T. Molina, G. Salles, 2017 .

Incidence and Outcomes of Treatment Refractory Diffuse Large B-Cell Lymphoma in the Immunochemotherapy Era

J. Cerhan, T. Habermann, S. Ansell, 2015 .

Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients Treated with Immunochemotherapy Who Are Alive and Progression Free 12 Months After Diagnosis Have a Subsequent Overall Survival Similar to That of the General Population

J. Cerhan, T. Habermann, S. Slager, 2012 .

Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial

F. Gao, R. Vij, J. Dipersio, 2023, Nature Medicine.

Everolimus Plus RCHOP-21 Is Safe and Highly Effective for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of the Phase I Trial NCCTG1085 (Alliance)

T. Habermann, S. Ansell, T. Witzig, 2015 .

90: Autologous Stem Cell Transplant (ASCT) in First Remission for Patients with Mantle Cell Lymphoma is Associated with Prolonged Survival

S. Ansell, D. Inwards, M. Siddiqui, 2008 .

Infused autograft lymphocyte-to-monocyte ratio and survival in T-cell lymphoma post-autologous peripheral blood hematopoietic stem cell transplantation

S. Ansell, S. Markovic, W. Hogan, 2015, Journal of Hematology & Oncology.

PD-1 Blockade with Pembrolizumab (MK-3475) in Relapsed/Refractory CLL Including Richter Transformation: An Early Efficacy Report from a Phase 2 Trial (MC1485)

Deborah A. Bowen, T. Habermann, T. Shanafelt, 2015 .

Phase 1 Trial of Sorafenib and Everolimus In Patients with Lymphoma or Multiple Myeloma.

S. Ansell, Shaji K. Kumar, M. Gertz, 2010 .

Abstract 2576: STAT3 tyrosine phosphorylation is frequent in diffuse large B cell lymphoma and is independent of molecular subtype: Implications for biomarker

T. Witzig, A. Dogan, Mamta Gupta, 2012 .

Absolute Lymphocyte/Monocyte Ratio at Diagnosis and Interim Positron-Emission Tomography Predict Survival in Classical Hodgkin Lymphoma

T. Habermann, S. Ansell, S. Markovic, 2013 .

A Phase I Trial of CpG-7909, Rituximab Immunotherapy, and Y90 Zevalin Radioimmunotherapy for Patients (Pts) with Previously Treated CD20+ Non-Hodgkin Lymphoma (NHL).

T. Habermann, T. Shanafelt, S. Ansell, 2007 .

Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines

T. Habermann, R. Fonseca, D. Dingli, 2010 .

IPI24: An International Study To Create An IPI For The Event-Free Survival At 24 Months (EFS24) Endpoint For DLBCL In The Immunochemotherapy Era

J. Cerhan, T. Molina, G. Salles, 2013 .

Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma.

P. Kurtin, T. Habermann, T. Witzig, 2011, Blood.

Defining The Optimal Threshold Of Peripheral Blood (PB) CD34+Cells To Initiate Apheresis In Patients With NHL Undergoing Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT) After G-CSF Mobilization

J. Dipersio, P. Stiff, P. Mody, 2010 .

Personalized risk prediction for event‐free survival at 24 months in patients with diffuse large B‐cell lymphoma

J. Cerhan, R. Gascoyne, C. Copie-Bergman, 2016, American journal of hematology.

S. Ansell, D. Inwards, L. Costa, 2008, British journal of haematology.